.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Julphar
Baxter
Cantor Fitzgerald
Fuji
QuintilesIMS
US Department of Justice
Healthtrust
Teva

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,015,577

« Back to Dashboard

Which drugs does patent 6,015,577 protect, and when does it expire?


Patent 6,015,577 protects AGGRENOX and is included in one NDA. There has been one Paragraph IV challenge on Aggrenox.

This patent has thirty-two patent family members in twenty-four countries.

Summary for Patent: 6,015,577

Title: Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation
Abstract:The specification describes a pharmaceutical combination consisting of dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing this pharmaceutical combination and the use thereof for the controlled prevention of clot formation.
Inventor(s): Eisert; Wolfgang (Biberach, DE), Gruber; Peter (Biberach, DE)
Assignee: Thomae GmbH; Dr. Karl (Biberach an der Riss, DE)
Application Number:08/421,351
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer IngelheimAGGRENOXaspirin; dipyridamoleCAPSULE, EXTENDED RELEASE;ORAL020884-001Nov 22, 1999ABRXYesYes► Subscribe► SubscribeTO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,015,577

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany36 27 423Aug 13, 1986

International Patent Family for Patent: 6,015,577

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria59961► Subscribe
Australia603146► Subscribe
Australia7679587► Subscribe
Brazil1100593► Subscribe
Canada1302272► Subscribe
Chile2004001252► Subscribe
German Democratic Republic263918► Subscribe
Germany10299015► Subscribe
Germany3627423► Subscribe
Germany3767408► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
AstraZeneca
Teva
Harvard Business School
Julphar
Argus Health
Boehringer Ingelheim
Novartis
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot